BCL2L11 and B-cell chronic lymphocytic leukemia: However, the increase in BIM levels as the driving force of the synergy may be a more possible hypothesis since not every CLL sample treated with both drugs ex vivo presented with altered anti-apoptotic BCL2 protein levels [62].